IMMUNEONCO-B (01541) recently observed unusual fluctuations in its share price. According to an announcement, the board of directors confirmed having no undisclosed information that would account for the changes and stated that the group’s business operations and clinical development remain normal.

Additionally, the announcement disclosed that the group received approval from the National Medical Products Administration for its Investigational New Drug application of IMM0306S (Subcutaneous Formulation) targeting Systemic Lupus Erythematosus. IMM0306S is based on IMM0306, which is a bispecific molecule targeting CD47 and CD20. The announcement noted that the group owns global intellectual property and commercial rights for IMM0306S. A cautionary statement highlighted no guarantee of the product’s eventual success in development or commercialization, advising investors to exercise due care.